Merck, north carolina and HPV vaccine

Merck opens $1B vaccine production facility (updated)
According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion toward U.S. capital investments it's made since 2018.
Merck opens $1 billion addition in north Durham to boost production of popular vaccine
The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.
Merck opens $1B Gardasil manufacturing facility in North Carolina
At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.
Merck opens manufacturing facility in North Carolina amid Trump's tariff threats
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump has been piling pressure on drugmakers since taking office to move medicine production to the U.
Merck Opens Vaccine Manufacturing Facility in North Carolina
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's tariff threats. Drugmakers have been exploring the possibility of government-granted exemptions for domestically manufactured medicines since Trump has threatened to impose 25% tariff on pharmaceutical imports.
Merck completes $1B North Carolina expansion — more growth on the way
A global health care company is growing its footprint in North Carolina with a $1 billion investment. Merck (NYSE: MRK) has opened a new 225,000-square-foot vaccine manufacturing facility in Durham. The pharmaceutical company,
FiercePharma23d
Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program
With Merck & Co. largely propping up supplies of the bladder cancer-fighting bacteria Bacillus Calmette-Guérin (BCG) in the U.S., ImmunityBio has received the FDA all-clear to help pick up the ...
Hosted on MSN22d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer. ImmunityBio said that Merck’s TICE BCG shortages have ...